Current Report Filing (8-k)
06 1월 2023 - 8:04PM
Edgar (US Regulatory)
0001307624
false
0001307624
2023-01-06
2023-01-06
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
______________
FORM 8-K
______________
CURRENT REPORT
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report
(Date of earliest event reported): January 6,
2023
______________
HEALTHTECH SOLUTIONS,
INC./UT
(Exact name of registrant
as specified in its charter)
______________
| Utah |
0-51012 |
84-2528660 |
| (State or Other Jurisdiction |
(Commission |
(I.R.S. Employer |
| of Incorporation) |
File Number) |
Identification No.) |
181 Dante Avenue,
Tuckahoe, New York 10707
(Address of Principal
Executive Office) (Zip Code)
844-926-3399
(Registrant’s telephone
number, including area code)
Securities
registered pursuant to Section 12(b) of the Act:
| Title of each class |
|
Trading
Symbol(s) |
|
Name of each exchange
on which registered |
| |
|
|
|
|
Check the appropriate box below if
the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check
mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth
company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| ITEM 7.01 REGULATION FD DISCLOSURE |
On January 6, 2023, the President of Healthtech Solutions
issued his annual letter to the shareholders and employees of Healthtech Solutions. A copy of the letter is furnished as Exhibit 99.1
to this current report.
The information in this Item 7.01 and Exhibit 99.1
hereto shall not be deemed “filed” for the purposes of or otherwise subject to the liabilities under Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”). Unless expressly incorporated into a filing by Healthtech Solutions
under the Securities Act of 1933, as amended, or the Exchange Act, the information contained in this Item 7.01 and Exhibit 99.1 hereto
shall not be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of
any general incorporation language in such filing.
| ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS |
Exhibits
| 99.1 |
Annual Letter to Shareholders dated January 6, 2023. |
| 104 |
Cover page interactive data file (embedded within the iXBRL document) |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto
duly authorized.
| |
Healthtech Solutions, Inc. |
| |
|
|
|
Date: January 6, 2023
|
By: |
/s/ Manuel E. Iglesias
Manuel E. Iglesias, President |
HealthTech Solutions (CE) (USOTC:HLTT)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024
HealthTech Solutions (CE) (USOTC:HLTT)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024
